Traws Pharma (TRAW)
NASDAQ:TRAW
Top Page
Traws Pharma
(NASDAQ:TRAW)
Select Model
Select Model
Rating:56Neutral
Price Target:
$2.00
▲(35.14% Upside)
Action:UpgradedDate:01/27/26
The score is held back primarily by weak financial performance (widening losses, rising cash burn, and negative equity), which elevates funding risk. Offsetting this are strong technical momentum (price above major moving averages with positive MACD) and multiple positive corporate catalysts tied to COVID and influenza pipeline progress, while valuation metrics are not supportive/meaningful given the loss-making profile.
Positive Factors
Pipeline clinical progress
Completing Phase 2 enrollment with favorable interim safety and efficacy signals materially raises the likelihood of clear next-step data readouts and regulatory discussions. Durable clinical momentum strengthens the company’s positioning versus ritonavir-based options and supports long-term commercial potential.
Negative Factors
Widening losses and accelerating cash burn
Rapidly increasing net losses and operating cash outflows materially shorten runway and raise near-term external funding needs. This structural cash consumption elevates dilution and execution risk, potentially forcing financing or program prioritization that could delay or curtail planned clinical milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline clinical progress
Completing Phase 2 enrollment with favorable interim safety and efficacy signals materially raises the likelihood of clear next-step data readouts and regulatory discussions. Durable clinical momentum strengthens the company’s positioning versus ritonavir-based options and supports long-term commercial potential.
Read all positive factors
Traws Pharma (TRAW) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.83M
Dividend YieldN/A
Average Volume (3M)206.36K
Price to Earnings (P/E)―
Beta (1Y)0.22
Revenue Growth1159.29%
EPS GrowthN/A
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.54
Shares Outstanding7,990,867
10 Day Avg. Volume403,079
30 Day Avg. Volume206,356
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.44
Price to Sales (P/S)61.01
P/FCF Ratio-0.46
Enterprise Value/Market Cap-0.02
Enterprise Value/Revenue-0.08
Enterprise Value/Gross Profit-0.08
Enterprise Value/Ebitda0.02
Forecast
1Y Price Target
$6.50Price Target Upside339.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.31
Revenue Forecast (FY)N/A
Traws Pharma Business Overview & Revenue Model
Company Description
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COV...
How the Company Makes Money
Traws Pharma generates revenue primarily through the sale of its pharmaceutical products and therapies that have gained regulatory approval. The company also engages in licensing agreements, where it grants other pharmaceutical firms access to its...
Traws Pharma Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:May 14, 2026
Earnings Call Sentiment Neutral
Traws Pharma has made notable advancements in its antiviral programs, particularly with Ratutrelvir for COVID-19. Regulatory engagement and a significant increase in revenue highlight positive progress. However, challenges such as deferred influenza studies and reduced cash reserves present concerns. Overall, highlights slightly outweigh the lowlights, indicating a cautiously optimistic outlook.Positive Updates
Strong Progress in Antiviral Development
Traws Pharma has reprioritized its clinical trial plans, advancing Ratutrelvir for COVID treatment, with Phase II study results expected by year-end 2025.
Negative Updates
Decrease in R&D and G&A Expenses
R&D expenses fell to $2.3 million from $4 million, and G&A expenses decreased to $1.7 million from $2 million, indicating reduced investment in some areas.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong Progress in Antiviral Development
Traws Pharma has reprioritized its clinical trial plans, advancing Ratutrelvir for COVID treatment, with Phase II study results expected by year-end 2025.
Read all positive updates
Company Guidance
During the second quarter of 2025, Traws Pharma provided guidance on their strategic focus areas, highlighting significant developments in their antiviral and influenza programs. They are advancing ratutrelvir, a ritonavir-free treatment for COVID-19, into Phase II studies, expecting results by the end of 2025, which could tap into a $1.5 billion market opportunity. Ratutrelvir aims to address the limitations of PAXLOVID, which saw a 70% sales increase to $427 million this quarter, by offering a longer treatment duration of 10 days and avoiding drug-drug interactions caused by ritonavir. Traws is also in discussions with BARDA for tivoxavir marboxil's potential inclusion in drug stockpiles for influenza, including bird flu, with recent protocol approvals in Australia and South Korea. Financially, Traws reported a net loss of $0.9 million for the quarter, a significant improvement from the $123.1 million loss in the same period of 2024, due to recognizing $2.7 million in deferred revenue following a licensing agreement termination. The company's cash reserves stood at $13.1 million, down from $21.3 million at the end of 2024.Traws Pharma Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.79M | 226.00K | 226.00K | 226.00K | 226.00K | 231.00K |
| Gross Profit | 2.79M | 214.00K | 226.00K | 226.00K | 226.00K | 231.00K |
| EBITDA | -10.97M | -166.51M | -20.28M | -19.61M | -16.48M | -24.98M |
| Net Income | -9.10M | -54.67M | -18.95M | -18.96M | -16.16M | -25.16M |
Balance Sheet | ||||||
| Total Assets | 15.62M | 24.96M | 22.68M | 39.37M | 55.48M | 19.99M |
| Cash, Cash Equivalents and Short-Term Investments | 13.08M | 21.34M | 20.82M | 38.76M | 55.07M | 19.02M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 7.36M | 56.59M | 12.01M | 11.06M | 9.36M | 13.81M |
| Stockholders Equity | 8.26M | -31.63M | 10.67M | 28.31M | 46.12M | 6.17M |
Cash Flow | ||||||
| Free Cash Flow | -10.02M | -29.79M | -17.95M | -16.29M | -19.49M | -23.09M |
| Operating Cash Flow | -10.02M | -29.79M | -17.93M | -16.29M | -19.49M | -23.07M |
| Investing Cash Flow | 0.00 | -3.65M | -14.00K | 0.00 | 0.00 | -15.00K |
| Financing Cash Flow | 23.07M | 33.98M | 0.00 | 0.00 | 55.56M | 19.36M |
Traws Pharma Technical Analysis
Negative
1.48
Price Trends
1.83
Negative
1.89
Negative
1.89
Negative
Market Momentum
-0.09
Positive
36.06
Neutral
5.36
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRAW, the sentiment is Negative. The current price of 1.48 is below the 20-day moving average (MA) of 1.87, below the 50-day MA of 1.83, and below the 200-day MA of 1.89, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 36.06 is Neutral, neither overbought nor oversold. The STOCH value of 5.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRAW.
Traws Pharma Risk Analysis
Traws Pharma disclosed 46 risk factors in its most recent earnings report. Traws Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Traws Pharma Peers Comparison
UnderperformOutperform
Sector (51)
TRAW
Traws Pharma
1.48
-0.64
-30.19%
LSTA
Lisata Therapeutics
5.01
3.05
155.61%
LEXX
Lexaria Bioscience
0.91
-0.50
-35.46%
HOTH
Hoth Therapeutics
0.52
-0.30
-37.20%
APLM
Apollomics
13.60
7.97
141.56%
Traws Pharma Corporate Events
Business Operations and StrategyProduct-Related Announcements
Traws Pharma Completes Phase 2 Enrollment for COVID Candidate
Positive
Jan 26, 2026
On January 26, 2026, Traws Pharma reported it had completed enrollment in a 90-patient open-label Phase 2 study of its oral COVID-19 candidate ratutrelvir, comparing it with PAXLOVID in PAXLOVID-eligible patients and in a separate cohort of patien...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Traws Pharma advances flu and COVID-19 antiviral pipeline
Positive
Jan 13, 2026
On January 13, 2026, Traws Pharma filed a U.S. Investigational New Drug application with the FDA for tivoxavir marboxil (TXM), a potential best-in-class, single-dose oral CAP-dependent endonuclease inhibitor for the treatment of seasonal and avian...
Business Operations and StrategyProduct-Related Announcements
Traws Pharma Reports Positive Phase 2 Trial Results
Positive
Dec 17, 2025
Traws Pharma announced positive interim results from a Phase 2 trial of ratutrelvir, a ritonavir-free oral COVID-19 treatment, on December 17, 2025. The data highlighted a favorable safety profile, no viral rebounds, and potential benefits for pat...
Business Operations and StrategyExecutive/Board Changes
Traws Pharma Approves Executive Stock Options
Neutral
Dec 16, 2025
On December 12, 2025, Traws Pharma‘s Compensation Committee approved stock options and restricted stock units for its executive officers. This decision, under the 2021 Incentive Compensation Plan, aims to incentivize key leaders, potentially...
Shareholder Meetings
Traws Pharma Holds Virtual Annual Meeting 2025
Neutral
Nov 28, 2025
On November 21, 2025, Traws Pharma held its Annual Meeting virtually, with 48% of its outstanding shares represented. During the meeting, stockholders elected seven directors, approved amendments to the 2021 Incentive Compensation Plan, and ratifi...
Business Operations and StrategyFinancial Disclosures
Traws Pharma Reports Q3 2025 Financial Results
Positive
Nov 13, 2025
On November 13, 2025, Traws Pharma announced its financial results for the quarter ending September 30, 2025, highlighting significant cost reductions and the acquisition of intellectual property assets. The company is advancing its Phase 2 studie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.